Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ABBV
stocks logo

ABBV

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
14.93B
+3.24%
3.183
+20.11%
15.34B
+6.1%
3.206
+6.86%
16.24B
+7.52%
3.372
+56.11%
Estimates Revision
The market is revising Upward the revenue expectations for AbbVie Inc. (ABBV) for FY2025, with the revenue forecasts being adjusted by 0.86% over the past three months. During the same period, the stock price has changed by -12.61%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.86%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.34%
In Past 3 Month
Stock Price
Go Down
down Image
-12.61%
In Past 3 Month
19 Analyst Rating
up Image0
Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 212.31 USD with a low forecast of 170.00 USD and a high forecast of 250.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
6 Hold
0 Sell
Moderate Buy
up Image0
Current: 185.490
sliders
Low
170.00
Averages
212.31
High
250.00
up Image0
Current: 185.490
sliders
Low
170.00
Averages
212.31
High
250.00
Citi
Buy
to
Neutral
downgrade
$210 -> $205
2025-05-14
Reason
Citi
Price Target
$210 -> $205
2025-05-14
downgrade
Buy
to
Neutral
Reason
Citi downgraded AbbVie to Neutral from Buy with a price target of $205, down from $210. While the company's current fundamentals are solid, the share impact from quarterly surprises could diminish going forward, especially as investors increasingly shift more focus to AbbVie's pipeline, the analyst tells investors in a research note. Citi cites the company's "comparatively lighter late-stage" pipeline versus its biopharma peers and a higher perceived policy risk than peers for the downgrade. Both of these add risk to AbbVie's "relative safety positioning," contends the firm.
Cantor Fitzgerald
Carter Gould
Buy
Initiates
$210
2025-04-22
Reason
Cantor Fitzgerald
Carter Gould
Price Target
$210
2025-04-22
Initiates
Buy
Reason
Guggenheim
Vamil Divan
Strong Buy
Reiterates
$214
2025-04-17
Reason
Guggenheim
Vamil Divan
Price Target
$214
2025-04-17
Reiterates
Strong Buy
Reason
Morgan Stanley
Terence Flynn
Buy
Maintains
$239 → $241
2025-04-09
Reason
Morgan Stanley
Terence Flynn
Price Target
$239 → $241
2025-04-09
Maintains
Buy
Reason
Morgan Stanley analyst Terence Flynn raised the firm's price target on AbbVie to $241 from $239 and keeps an Overweight rating on the shares. The firm adjusted its large cap pharma and biotech models for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting season for the group.
Goldman Sachs
Asad Haider
Hold
Initiates
$194
2025-04-08
Reason
Goldman Sachs
Asad Haider
Price Target
$194
2025-04-08
Initiates
Hold
Reason
Wells Fargo
Mohit Bansal
Buy
Maintains
$210 → $240
2025-03-05
Reason
Wells Fargo
Mohit Bansal
Price Target
$210 → $240
2025-03-05
Maintains
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for AbbVie Inc (ABBV.N) is 16.89, compared to its 5-year average forward P/E of 12.10. For a more detailed relative valuation and DCF analysis to assess AbbVie Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PE
12.10
Current PE
16.89
Overvalued PE
15.08
Undervalued PE
9.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
11.44
Current EV/EBITDA
13.44
Overvalued EV/EBITDA
13.46
Undervalued EV/EBITDA
9.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PS
4.55
Current PS
5.50
Overvalued PS
5.46
Undervalued PS
3.64

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress areBuying! The buying amount has increased126.56%over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

ABBV News & Events

Events Timeline

(ET)
2025-06-18
07:17:44
AbbVie reports results from Phase 3 TEMPLE multicenter study
select
2025-06-16 (ET)
2025-06-16
11:56:58
Roche, AbbVie say Phase III VERONA study faliled in MDS
select
2025-06-16
11:42:40
Roche, AbbVie says Phase III VERONA study faliled in MDS
select
Sign Up For More Events
Sign Up For More Events

News

Preview
9.0
06-19Benzinga
PinnedAbbVie's Migraine Drug Outperforms Generic Treatment In Head-To-Head Trial

  • Atogepant Study Results: AbbVie Inc's Phase 3 TEMPLE study showed that atogepant (QULIPTA/AQUIPTA) had a significantly lower discontinuation rate due to adverse events compared to topiramate, with 12.1% versus 29.6%, and also demonstrated better efficacy in reducing monthly migraine days.

  • Market Impact: Following the positive study results, ABBV stock increased by 0.48% to $186.36, while AbbVie also reported that another trial for venetoclax did not meet its primary endpoint for overall survival.

Preview
9.0
06-18NASDAQ.COM
PinnedAbbVie Reports Positive Topline Results From Phase 3 TEMPLE Study Of Atogepant For Migrane

  • Study Results: AbbVie, Inc. announced positive results from its Phase 3 TEMPLE study showing that atogepant (QULIPTA/AQUIPTA) is more tolerable and effective than topiramate for preventing migraines in adults with frequent migraine days.

  • Efficacy Comparison: Atogepant demonstrated a significantly lower discontinuation rate due to adverse events (12.1% vs. 29.6%) and a higher percentage of patients achieving a 50% reduction in monthly migraine days compared to topiramate (64.1% vs. 39.3%).

Preview
9.0
06-18Yahoo Finance
PinnedAbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention

  • Study Results: The Phase 3 TEMPLE study demonstrated that atogepant significantly reduced treatment discontinuations due to adverse events compared to topiramate, and met all secondary endpoints for migraine prevention efficacy.

  • Clinical Implications: Atogepant's positive results support its role as a first-line preventive treatment for migraines, addressing the unmet needs of patients who often struggle with current therapies.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is AbbVie Inc (ABBV) stock price today?

The current price of ABBV is 185.49 USD — it has increased 0.01 % in the last trading day.

arrow icon

What is AbbVie Inc (ABBV)'s business?

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.

arrow icon

What is the price predicton of ABBV Stock?

Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 212.31 USD with a low forecast of 170.00 USD and a high forecast of 250.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is AbbVie Inc (ABBV)'s revenue for the last quarter?

AbbVie Inc revenue for the last quarter amounts to 13.34B USD, increased 8.39 % YoY.

arrow icon

What is AbbVie Inc (ABBV)'s earnings per share (EPS) for the last quarter?

AbbVie Inc. EPS for the last quarter amounts to 0.72 USD, decreased -6.49 % YoY.

arrow icon

What changes have occurred in the market's expectations for AbbVie Inc (ABBV)'s fundamentals?

The market is revising Upward the revenue expectations for AbbVie Inc. (ABBV) for FY2025, with the revenue forecasts being adjusted by 0.86% over the past three months. During the same period, the stock price has changed by -12.61%.
arrow icon

How many employees does AbbVie Inc (ABBV). have?

AbbVie Inc (ABBV) has 55000 emplpoyees as of June 20 2025.

arrow icon

What is AbbVie Inc (ABBV) market cap?

Today ABBV has the market capitalization of 327.65B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free